Effect of postoperative administration of nafamostat mesilate on posthepatectomy liver failure

Abstract

To investigate whether the administration of nafamostat mesilate (NM) reduces the risk of posthepatectomy liver failure (PHLF) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC). We retrospectively reviewed the 1114 patients who underwent hepatectomy for HCC between 2004 and 2020. NM was selectively administered to patients undergoing major hepatectomy with an estimated blood loss of >500mL. NM group was administered via intravenous of 20mg of NM from immediately after surgery until postoperative day 4. We performed 1:1 propensity score matching and included 56 patients in each group. PHLF was defined according to the International Study Group of Liver Surgery (ISGLS). The incidence of PHLF was lower in the NM group than control group (P=0.018). The mean peak total bilirubin (P=0.006), aspartate transaminase (P=0.018), and alanine aminotransferase (P=0.018) levels postoperatively were significantly lower in the NM group. The mean hospital stays (P=0.012) and major complication rate (P=0.023) were also significantly lower in the NM group. Prophylactic administration of NM reduced the risks of complication and decreased the frequency of PHLF after hepatectomy. A further prospective study is needed to verify our findings.